Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

108.40
-0.4000-0.37%
Pre-market: 108.890.4900+0.45%07:04 EDT
Volume:641.06K
Turnover:69.40M
Market Cap:4.93B
PE:52.88
High:109.49
Open:108.02
Low:107.38
Close:108.80
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.56
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.89
PE(LYR):52.88

Loading ...

Haemonetics combines Plasma and Blood Center units into new Apheresis reporting segment

Reuters
·
Jun 05

Haemonetics Updates Financial Reporting Segments

THOMSON REUTERS
·
Jun 05

Haemonetics - to Report Under New Segment Structure Beginning Q1 FY2027

THOMSON REUTERS
·
Jun 05

Haemonetics CEO Simon to speak at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 03

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

GlobeNewswire
·
May 29

Haemonetics Is Maintained at Neutral by Citigroup

Dow Jones
·
May 29

New Data Highlights Heavy Burden of Injectable Treatments for Young HAE Patients

Deep News
·
May 28

Haemonetics price target raised to $70 from $64 at Citi

TIPRANKS
·
May 28

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewswire
·
May 27

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

MT Newswires Live
·
May 22

Haemonetics Raised to Buy From Neutral by B of A Securities

Dow Jones
·
May 22

BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80

MT Newswires Live
·
May 22

Haemonetics upgraded to Buy from Neutral at BofA

TIPRANKS
·
May 22

Haemonetics’ Global ERP Rollout Poses Execution Risks, Potential Margin Pressure and Operational Disruption

TIPRANKS
·
May 22

Haemonetics FY26 net income drops 42% to $97.31 million; revenue slips 2% to $1.33 billion

Reuters
·
May 20

Haemonetics (HAE) Valuation Check As Earnings Pressure And Options Volatility Raise Questions

Simply Wall St.
·
May 18

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

GlobeNewswire
·
May 13

Haemonetics Is Maintained at Outperform by Barrington Research

Dow Jones
·
May 13

Press Release: Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13